This article was written by Edward Mwangi and Jacques Georget
Opportunity Summary
Mylan’s merger with Pfizer’s Upjohn division, which almost exclusively offers generic drugs, will provide an addition to the product portfolio. It will also provide new capital to finance innovation for new product launches which are a focal point of growth for the company. Opportunities in the stock include synergies from the new entity, a wider product range and high immediate sales due to off-patent drugs like Viagra, Epipen, and Lipitor to boost earnings. Finally, UpJohn post higher operating margins than Mylan and we,